Published in Neural Regen Res on September 25, 2012
Cross interaction of melanocortinergic and dopaminergic systems in neural modulation. Int J Physiol Pathophysiol Pharmacol (2015) 0.85
Oxidants, oxidative stress and the biology of ageing. Nature (2000) 23.21
Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci (2006) 4.87
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol (2006) 1.44
Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol (1998) 1.43
Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21
Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? J Neurochem (2010) 1.05
Resonance Raman studies on the blue-green-colored bovine adrenal tyrosine 3-monooxygenase (tyrosine hydroxylase). Evidence that the feedback inhibitors adrenaline and noradrenaline are coordinated to iron. J Biol Chem (1988) 1.04
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry (2007) 1.01
Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr Neurosci (2012) 0.99
Therapeutic approach to neurodegenerative diseases by medical gases: focusing on redox signaling and related antioxidant enzymes. Oxid Med Cell Longev (2012) 0.98
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model. J Nutr Biochem (2012) 0.90
Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des (2010) 0.90
Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem Res (2012) 0.85
Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson's disease: therapeutic perspectives. Nutrition (2012) 0.83
From genes to proteins in mendelian Parkinson's disease: an overview. Anat Rec (Hoboken) (2009) 0.83
Free-radical toxicity and antioxidant medications in Parkinson's disease. Phys Ther (1998) 0.81
The role of dopamine replacement on the behavioural phenotype of Parkinson's disease. Behav Neurol (2013) 0.80
[Inhibitory effect of hypoxanthine on monoamine oxidase activity]. Yao Xue Xue Bao (1989) 0.79
Parkinson's disease. Adv Nurse Pract (1998) 0.78
[Preliminary experimental study on therapeutic mechanism of kangzhen zhijing capsule in treating Parkinson's disease]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2001) 0.78